



Trial Information Summary

ALLG Trial Number:	ALL08
Trial Name:	BLAM - A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia
Lay Summary:	<p>The aim of this study is to afford adult patients with Acute Lymphoblastic Leukaemia (who are not eligible for treatment with chemotherapy protocols based upon childhood leukaemia protocols) effective treatment with a novel agent. The study will also demonstrate the safety and effectiveness of replacing blocks of toxic chemotherapy with better tolerated novel therapies. Blinatumomab is a novel drug which utilises the patient's own immune system to target the leukaemia cells and has demonstrated superiority in patients with disease which has either come back after initial therapy or not responded to initial therapy when compared to standard chemotherapy. It is given by a long-term infusion necessitating the use of a take-home pump for portions of the therapy. This study seeks to replace a portion of the standard leukaemia therapy with Blinatumomab, to improve both disease outcomes (response and survival) and the tolerability of therapy. Patients receive initial chemotherapy at low doses to reduce the amount of disease in the bone marrow, followed by Blinatumomab alternating with conventional chemotherapy. Finally, patients will receive 2-years of low dose chemotherapy maintenance to reduce the risk of late disease relapse.</p>
Participating Hospitals:	1. Alfred
Target Accrual (International):	N/A
Target Accrual (ALLG):	30 Patients
Expected Final Accrual Date:	April 2020